Review
Biochemistry & Molecular Biology
Shiva Nasr, Athar Nakisa, Setareh Jandaghian, Monireh Kouhi, Erfan Sadeghi, Jaleh Varshosaz
Summary: This systematic review found that flavonoid supplements do not have a significant effect on IGF-1 and IGFBP-3. However, a high soy diet has beneficial effects on components of the IGF system, which may be useful in breast cancer.
CURRENT MEDICINAL CHEMISTRY
(2023)
Article
Multidisciplinary Sciences
James R. W. Conway, Defne D. Dinc, Gautier Follain, Oona Paavolainen, Jasmin Kaivola, Pia Bostroem, Pauliina Hartiala, Emilia Peuhu, Johanna Ivaska
Summary: The progression from noninvasive ductal carcinoma in situ to invasive ductal carcinoma in breast cancer patients has a negative impact on prognosis and can lead to metastasis. Insulin-like growth factor-binding protein 2 (IGFBP2) secreted by healthy breast adipocytes has been identified as a potent adipocrine factor that acts as a barrier against invasive progression. Adipocytes derived from patient stromal cells were found to secrete IGFBP2, which effectively inhibited breast cancer invasion by sequestering cancer-derived IGF-II. Depleting IGF-II in invading cancer cells using RNAs or an IGF-II-neutralizing antibody prevented breast cancer invasion, emphasizing the importance of IGF-II autocrine signaling in invasive progression.
Article
Geriatrics & Gerontology
Joung-Kyue Han, Gangmi Kim
Summary: This study analyzed 12 randomized controlled trials involving 736 participants and found that physical exercise significantly reduced levels of serum insulin, IGF-II, IGFBP-1, and HOMA score in women with breast cancer. Additionally, serum glucose and IGF-I levels decreased after physical exercise although they did not show statistical significance.
EXPERIMENTAL GERONTOLOGY
(2021)
Review
Endocrinology & Metabolism
Derek LeRoith, Jeff M. P. Holly, Briony E. Forbes
Summary: The IGF family of ligands, receptors, and binding proteins play critical roles in normal human physiology and disease states. IGF-I regulates cellular growth, differentiation, and survival to control overall body growth, while IGF-II has important effects prenatally and in tissue-specific roles in adults.
MOLECULAR METABOLISM
(2021)
Review
Biology
Ji-Sun Lee, Claire E. Tocheny, Leslie M. Shaw
Summary: This review provides an overview of the role of the IGF signaling pathway in breast cancer and discusses its potential as a therapeutic target. Dysregulation of IGF pathway components contributes to breast cancer risk and progression, and the pathway has also been implicated in resistance to current therapies. Unfortunately, targeting IGF signaling for breast cancer treatment has been unsuccessful so far due to adverse effects on normal glucose metabolism. However, recent discoveries offer hope for continued efforts in this area.
Review
Oncology
Jennifer A. Waters, Ixchel Urbano, Mikella Robinson, Carrie D. House
Summary: This review discusses the different roles of IGF signaling and IGFBP5 in disease, emphasizing the need to clarify the IGF-independent actions of IGFBP5, the impact of its subcellular localization, the differential activities of each subdomain, and the response to elements of the tumor microenvironment (TME). Recent advances addressing the role of IGFBP5 in resistance to cancer therapeutics are also discussed.
FRONTIERS IN ONCOLOGY
(2022)
Review
Chemistry, Medicinal
Fatemeh Meshkini, Nahid Ramezani-Jolfaie, Saman Sargazi, Cain C. T. Clark, Sepideh Soltani
Summary: A systematic review of the effects of lycopene on circulating IGF-1 and IGFBPs in adults found no consistent modifying effect of lycopene supplementation on IGF-1 and IGFBP levels. More research is needed to explore the effect of lycopene on the IGF-1 system.
PHYTOTHERAPY RESEARCH
(2022)
Review
Endocrinology & Metabolism
Tanvi Mathur, Douglas Yee
Summary: Inhibitors targeting IGF-1R have not shown additional benefits in clinical trials, possibly due to the prevalent expression of IR-A in cancer. Developing isoform-specific inhibitors targeting IR-A could serve as a predictive biomarker and cotargeting IR-A and IGF-1R could potentially provide a novel and more effective therapy approach.
Article
Oncology
Alison E. Obr, Joseph J. Bulatowicz, Yun-Juan Chang, Virginia Ciliento, Alexander Lemenze, Krystopher Maingrette, Quan Shang, Emily J. Gallagher, Derek LeRoith, Teresa L. Wood
Summary: The reduction of IGF1R expression is associated with the upregulation of pathways necessary for promoting metastasis in breast cancer. Functional analysis reveals that decreased IGF1R signaling leads to a dysregulation of cadherin expression, resulting in reduced cell adhesion.
FRONTIERS IN ONCOLOGY
(2022)
Review
Endocrinology & Metabolism
Mengyang Li
Summary: The GH/IGF system plays a role in growth regulation in the body. By studying the basal chordate amphioxus, it was discovered that most members of the GH/IGF system are present in amphioxus, providing strong evidence for the origin of this system in amphioxus.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Veronica Vella, Marika Giuliano, Maria Luisa Nicolosi, Maria Giovanna Majorana, Malgorzata Anna Marc, Maria Grazia Muoio, Andrea Morrione, Marcello Maggiolini, Rosamaria Lappano, Ernestina Marianna De Francesco, Antonino Belfiore
Summary: The study suggests that DDR1 may function as a novel regulator of breast cancer metabolism independently of IR/IGF1R stimulation, making it a potential target for therapy in breast cancer.
Article
Oncology
Fanxiu Xiong, Jingxuan Wang, Jovia L. Nierenberg, Erin L. Van Blarigan, Stacey A. Kenfield, June M. Chan, Gabriela Schmajuk, Chiung-Yu Huang, Rebecca E. Graff
Summary: The objective of this study was to evaluate the associations between overall diabetes, type 1 diabetes (T1D), type 2 diabetes (T2D), and breast cancer risk. The study found no overall association between diabetes and breast cancer risk, but revealed that women with T1D had a higher risk of breast cancer compared to women without diabetes. T2D was not associated with breast cancer risk overall, but there was a significantly increased risk in the short time window after T2D diagnosis.
BRITISH JOURNAL OF CANCER
(2023)
Article
Cell Biology
Ke Li, Ting-ting Zhang, Chen-xi Zhao, Feng Wang, Bing Cui, Zhao-na Yang, Xiao-xi Lv, Zaiwuli Yeerjiang, Yu-fen Yuan, Jin-mei Yu, Zhen-he Wang, Xiao-wei Zhang, Jiao-jiao Yu, Shan-shan Liu, Shuang Shang, Bo Huang, Fang Hua, Zhuo-wei Hu
Summary: The study showed that FGD5 is associated with poor prognosis in BLBCs and interacts with EGFR in BLBC cells, affecting cell proliferation, invasion, and tumorsphere formation, providing a potential therapeutic option for BLBC.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Medicine, General & Internal
Layla Damen, Melitza S. M. Elizabeth, Stephany H. Donze, Sjoerd A. A. van den Berg, Laura C. G. de Graaff, Anita C. S. Hokken-Koelega
Summary: In children with Prader-Willi syndrome receiving GH treatment, high immunoreactive IGF-I levels are often observed, while free IGF-I levels are low, indicating a significant discrepancy between the two.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Afsaneh Mennati, Kobra Rostamizadeh, Hamidreza Kheiri Manjili, Mojtaba Fathi, Hossein Danafar
Summary: The study demonstrates that mPEG-PCL-DDAB nanoparticles possess suitable physicochemical properties for delivery to tumor cells and have the potential to induce apoptosis in breast cancer cell lines.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2022)
Article
Endocrinology & Metabolism
Luke Arentsen, Karen E. Hansen, Masashi Yagi, Yutaka Takahashi, Ryan Shanley, Angela McArthur, Patrick Bolan, Taiki Magome, Douglas Yee, Jerry Froelich, Susanta K. Hui
JOURNAL OF BONE AND MINERAL METABOLISM
(2017)
Article
Radiology, Nuclear Medicine & Medical Imaging
Patrick J. Bolan, Eunhee Kim, Benjamin A. Herman, Gillian M. Newstead, Mark A. Rosen, Mitchell D. Schnall, Etta D. Pisano, Paul T. Weatherall, Elizabeth A. Morris, Constance D. Lehman, Michael Garwood, Michael T. Nelson, Douglas Yee, Sandra M. Polin, Laura J. Esserman, Constantine A. Gatsonis, Gregory J. Metzger, David C. Newitt, Savannah C. Partridge, Nola M. Hylton
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2017)
Review
Endocrinology & Metabolism
Douglas Yee
JOURNAL OF MOLECULAR ENDOCRINOLOGY
(2018)
Article
Oncology
Yuzhe Yang, Jie Ying Chan, Nuri A. Temiz, Douglas Yee
Article
Nutrition & Dietetics
Hamed Samavat, Anna H. Wu, Giske Ursin, Carolyn J. Torkelson, Renwei Wang, Mimi C. Yu, Douglas Yee, Mindy S. Kurzer, Jian-Min Yuan
JOURNAL OF NUTRITION
(2019)
Review
Endocrinology & Metabolism
Tanvi Mathur, Douglas Yee
Summary: Inhibitors targeting IGF-1R have not shown additional benefits in clinical trials, possibly due to the prevalent expression of IR-A in cancer. Developing isoform-specific inhibitors targeting IR-A could serve as a predictive biomarker and cotargeting IR-A and IGF-1R could potentially provide a novel and more effective therapy approach.
Article
Oncology
Beverly Moy, R. Bryan Rumble, Steven E. Come, Nancy E. Davidson, Angelo Di Leo, Julie R. Gralow, Gabriel N. Hortobagyi, Douglas Yee, Ian E. Smith, Mariana Chavez-MacGregor, Rita Nanda, Heather L. McArthur, Laura Spring, Katherine E. Reeder-Hayes, Kathryn J. Ruddy, Paul S. Unger, Shaveta Vinayak, William J. Irvin, Avan Armaghani, Michael A. Danso, Natalie Dickson, Sophie S. Turner, Cheryl L. Perkins, Lisa A. Carey
Summary: This guideline provides recommendations on chemotherapy and targeted therapy for patients with HR-negative metastatic breast cancer, offering different treatment options based on patient's condition, such as combination chemotherapy, single-agent chemotherapy, or targeted therapy. Specific treatment options are also suggested for patients with different genetic mutations.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. Van't Veer, Donald A. Berry, Laura J. Esserman
Summary: The study found that further development of anti-IGF-1R therapy will require better control of drug-induced hyperglycemia and the development of more predictive biomarkers.
Article
Oncology
Xuanzi Qin, Peter Huckfeldt, Jean Abraham, Douglas Yee, Beth A. Virnig
Summary: Generic entry of aromatase inhibitors (AIs) allows for increased switching, which leads to improved adherence and better management of treatment-related side effects. However, patients and physicians may lack understanding of Part D benefit design, highlighting the need for improved education and communication to enhance decision-making.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Oncology
Jayanthi Vijayakumar, Tufia Haddad, Kalpna Gupta, Janet Sauers, Douglas Yee
Summary: The clinical activity of naltrexone in patients with ER-positive metastatic breast cancer was evaluated. The results showed that naltrexone exhibited modest activity in stabilizing or reducing tumor SUVmax values in this short study. However, further development of the drug in hormone refractory breast cancer is not supported.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Oncology
Julie E. Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A. Parker, A. Jo Chien, Anne M. Wallace, Rashmi Murthy, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Rachel L. Yung, Claudine Isaacs, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Erica Stringer-Reasor, Elissa Price, Bonnie Joe, Minetta C. Liu, Lamorna Brown-Swigart, Emanuel F. Petricoin, Julia D. Wulfkuhle, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van't Veer, Nola M. Hylton, Angela M. DeMichele, Donald A. Berry, Laura J. Esserman
Summary: Ganetespib, an HSP90 inhibitor, combined with standard chemotherapy did not significantly increase the pathologic complete response (pCR) rates in patients with high-risk early-stage breast cancer, and the HSP90 pathway and replicative stress expression markers did not predict response.
Article
Biochemistry & Molecular Biology
Bhumika Rajoria, Xihong Zhang, Douglas Yee
Summary: The Insulin-like Growth Factor (IGF) system has long been studied in breast cancer progression, but targeting it has not been successful due to the complexity and homology of its receptors. This study examined the metabolic phenotype of breast cancer cells upon stimulation with IGF-1 and insulin. The results showed that IGF-1R, but not IR, regulates ATP production, providing evidence of the relationship between metabolic dysfunction, cancer, and the IGF axis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Endocrinology & Metabolism
Xihong Zhang, Sidhant Varma, Douglas Yee
Summary: Inhibition of IRS-1 protein can suppress both IGFR-IR and IR, leading to inhibition of growth and regulation in hormone-dependent breast cancer cells. This study reveals the crucial role of IRS-1 in endocrine responsive breast cancer.
Article
Genetics & Heredity
Michael A. Carpenter, Nuri A. Temiz, Mahmoud A. Ibrahim, Matthew C. Jarvis, Margaret R. Brown, Prokopios P. Argyris, William L. Brown, Gabriel J. Starrett, Douglas Yee, Reuben S. Harris
Summary: The single-stranded DNA cytosine deamination by APOBEC3 enzymes is a significant source of mutation in cancer, and both APOBEC3A and APOBEC3B contribute to the overall mutation landscape.
Article
Oncology
Hamed Samavat, Giske Ursin, Tim H. Emory, Eunjung Lee, Renwei Wang, Carolyn J. Torkelson, Allison M. Dostal, Karen Swenson, Chap T. Le, Chung S. Yang, Mimi C. Yu, Douglas Yee, Anna H. Wu, Jian-Min Yuan, Mindy S. Kurzer
CANCER PREVENTION RESEARCH
(2017)